Germany Is New Battlefield for Drugmakers Facing Price Scrutiny
- Roche says innovative medicines are made available in Germany
- Novo Nordisk, Bayer pulled key new drugs from the nation
This article is for subscribers only.
Germany, Europe’s largest market for drugs, is emerging as a new front in the battle on drug pricing for pharmaceutical companies already engaged in skirmishes with U.S. health insurers and legislators.